Ligand Pharmaceuticals Incorporated (LGND) Q4 2015 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.47%

Ligand Pharmaceuticals reported a positive surprise on EPS, indicating better-than-expected profitability. However, the stock fell by 1.47% on the day, likely due to the lack of revenue details and forward guidance. Investors may be cautious as they await more information on future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.66	N/A	+29.41%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of optimism about the company's direction. However, they did not offer specific guidance for the upcoming quarters.

Management highlighted the strong performance in their core business.

They expressed confidence in future growth despite not providing specific guidance.

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.47%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 1.47%

Key numbers

Management commentary